Dtc Genetics Company Nucleus Genomics Raises $18 Million In Funding In One Year

Jul 14, 2022•about 3 years ago

Amount Raised

$18 Million

BrooklynOtherHealth CareSoftware

Description

Nucleus Genomics, a next-generation consumer genetic testing and analysis company, has raised $14 million in a new funding round led by Alexis Ohanian's Seven Seven Six. The NYC-based company, founded by Kian Sadeghi, is building a DTC genetic testing platform that provides innovative genetic risk and disposition score analyses on an extensive number of diseases and traits by leveraging whole-genome sequencing (WGS). The company also believes in maximal data ownership and liberty by providing its users total autonomy over their genetic data.

Company Information

Company

Nucleus Genomics

Location

Brooklyn, New York, United States

About

Since then, the company has received FDA approval for a number of genetic tests that quantify health risks for conditions like Parkinson’s or breast cancer, to name a few. But as for regulatory strategy, the company initially plans to go a route once used by Ancestry – order tests from a clinical network, rather than creating their own. That does allow the company to sidestep FDA approval of its algorithms at first (this process is regulated by the Centers for Medicare and Medicaid). In the meantime, the company plans to launch sometime around January 2022 and has plans to grow the team from three to six or seven members. “It’s an imminent inevitability that every person has the human genome sequence,” said Sadeghi.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech